Locked Nucleic Acid Gapmers and Conjugates Potently Silence ADAM33, an Asthma-Associated Metalloprotease with Nuclear-Localized mRNA-Reference-Cited by-同舟云学术

Locked Nucleic Acid Gapmers and Conjugates Potently Silence ADAM33, an Asthma-Associated Metalloprotease with Nuclear-Localized mRNA

Published:2017-09 Issue: Volume:8 Page:158-168
ISSN:2162-2531
Container-title:Molecular Therapy - Nucleic Acids
language:en
Short-container-title:Molecular Therapy - Nucleic Acids

Author:

Pendergraff Hannah M.,Krishnamurthy Pranathi Meda,Debacker Alexandre J.,Moazami Michael P.,Sharma Vivek K.,Niitsoo Liisa,Yu Yong,Tan Yen Nee,Haitchi Hans Michael,Watts Jonathan K.

Funder

Institute for Life Sciences

UMass Medical School

Engineering and Physical Sciences Research Council

Medical Research Council (MRC) Clinician Scientist Fellowship

Publisher

Elsevier BV

Subject

Drug Discovery,Molecular Medicine

Reference71 articles.

1. Evidence of a genetic contribution to lung function decline in asthma;Koppelman;J. Allergy Clin. Immunol.,2011

2. Airway remodelling in asthma: current understanding and implications for future therapies;Tang;Pharmacol. Ther.,2006

3. Global Asthma Network. (2014). The global asthma report. http://globalasthmareport.org.

4. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness;Van Eerdewegh;Nature,2002

5. ADAM33 polymorphism: association with bronchial hyper-responsiveness in Korean asthmatics;Lee;Clin. Exp. Allergy,2004

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Modular Albumin-Oligonucleotide Biomolecular Assembly for Delivery of Antisense Therapeutics;Molecular Pharmaceutics;2024-01-12

2. Heterozygous nonsense variants in the ferritin heavy-chain gene FTH1 cause a neuroferritinopathy;Human Genetics and Genomics Advances;2023-10

3. Propensities of Fatty Acid-Modified ASOs: Self-Assembly vs Albumin Binding;Bioconjugate Chemistry;2023-05-05

4. Production of sterile Atlantic salmon by germ cell ablation with antisense oligonucleotides;2023-04-14

5. Enhancing the Effectiveness of Oligonucleotide Therapeutics Using Cell-Penetrating Peptide Conjugation, Chemical Modification, and Carrier-Based Delivery Strategies;Pharmaceutics;2023-04-03